Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: Results of the AIDA-2000 trial of the GIMEMA Group

Blood

Volumn 116, Issue 17, 2010, Pages 3171-3179

  Lo Coco, Francesco ^a,b   Avvisati, Giuseppe ^c   Vignetti, Marco ^d   Breccia, Massimo ^d   Gallo, Eugenio ^e   Rambaldi, Alessandro ^f   Paoloni, Francesca ^g   Fioritoni, Giuseppe ^h   Ferrara, Felicetto ⁱ   Specchia, Giorgina ^j   Cimino, Giuseppe ^d   Diverio, Daniela ^d   Borlenghi, Erika ^k   Martinelli, Giovanni ^l   Di Raimondo, Francesco ^m   Di Bona, Eros ⁿ   Fazi, Paola ^g   Peta, Antonio ^o   Bosi, Alberto ^p   Carella, Angelo M ^q   Fabbiano, Francesco ^r   Pogliani, Enrico M ^s   Petti, Maria C ^t   Amadori, Sergio ^a   Mandelli, Franco ^g   more..

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^c UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e MAGGIORE HOSPITAL   (Italy)

^f OSPEDALI RIUNITI   (Italy)

^g Fondazione GIMEMA ONLUS   (Italy)

^h UO Ematologia Clinica   (Italy)

ⁱ CARDARELLI HOSPITAL   (Italy)

^j UNIVERSITY OF BARI   (Italy)

^k SPEDALI CIVILI   (Italy)

^l UNIVERSITY OF BOLOGNA   (Italy)

^m UNIVERSITY OF CATANIA   (Italy)

ⁿ SAN BORTOLO HOSPITAL   (Italy)

^o PUGLIESE CIACCIO HOSPITAL   (Italy)

^p UNIVERSITY OF FLORENCE   (Italy)

^q UNIVERSITY OF GENOA   (Italy)

^r AOV Cervello   (Italy)

^s Divisione di Ematologia SGerardo dei Tintori   (Italy)

^t REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; IDARUBICIN; MERCAPTOPURINE; METHOTREXATE; MITOXANTRONE; PREDNISONE; RETINOIC ACID; TIOGUANINE; TRANEXAMIC ACID;

ADULT; ARTICLE; BLEEDING; CANCER RELAPSE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; INCIDENCE; INFECTION; KIDNEY FAILURE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; RANDOMIZED CONTROLLED TRIAL; REMISSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL SIGNIFICANCE; THROMBOCYTE COUNT; THROMBOEMBOLISM; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 77958499078     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-03-276196     Document Type: Article

References (22)

1. Tallman MS, Altman JK. Curative strategies in acute promyelocytic leukemia. Hematology Am Soc Hematol Educ Program. 2008;391-399.
2. Ades L, Guerci A, Raffoux E, et al. Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience. Blood. 2010;115(9):1690-1696.
3. Sanz MA, Grimwade D, Tallman MS, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2009;113(9): 1875-1891.
4. Sanz MA, Lo-Coco F, Martin G, et al. Definition of relapse risk and role of non-anthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood. 2000;96(4): 1247-1253. (Pubitemid 30658450)
5. Sanz MA, Martin G, Rayòn C, et al. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RAR alpha-positive acute promyelocytic leukemia. Blood. 1999;94(9):3015-3021.
6. Sanz MA, Montesinos P, Vellenga E, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA group. Blood. 2008;112(8):3130-3134.
7. Mandelli F, Diverio D, Avvisati G, et al. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy: Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. Blood. 1997;90(3):1014-1021.
8. Testi AM, Biondi A, Lo-Coco F, et al. GIMEMA-AIEOP- AIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children. Blood. 2005;106(2):447-453.
9. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinuim thiocyanatephenol- chloroform extraction. Anal Biochem. 1987;162(1):156-159.
10. de la Serna J, Montesinos P, Vellenga E, et al. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood. 2008;111(7):3395-3402.
11. Ades L, Sanz MA, Chevret S, et al. Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results. Blood. 2008;111(3):1078-1084.
12. Burnett AK, Hills RK, Grimwade D, et al. Idarubicin and ATRA is as effective as MRC chemotherapy in patients with acute promyelocytic leukemia with lower toxicity and resource U S Age: preliminary results of the MRC AML15 trial [abstract]. Blood. 2007;110:181a.
13. Lo-Coco F, Avvisati G, Vignetti M, et al. Font-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation: results of the AIDA-2000 trial of the Italian GIMEMA group [abstract]. Blood. 2004;104:392a.
14. Sanz MA, Montesinos P, Rayon C, et al. Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high risk: further improvements in treatment outcome. Blood. 2010;115(25):5137-5146.
15. Flanagan SA, Meckling KA. All-trans retinoic acid increases cytotoxicity of 1-beta-D-arabinofuranosylcytosine in NB4 cells. Cancer Chemother Pharmacol. 2003;51(5):363-375. (Pubitemid 36649133)
16. Jasek E, Mirecka J, Litwin JA. Effect of differentiating agents (all-trans retinoic acid and phorbol 12-myristate 13-acetate) on drug sensitivity of HL60 and NB4 cells in vitro. Folia Histochem Cytobiol. 2008;46(3):323-330.
17. Powell BL. Effect of consolidation with arsenic trioxide (As2O3) on event-free survival (EFS) and overall survival (OS) among patients with newly diagnosed acute promyelocytic leukemia (APL): North American Intergroup Protocol C9710. 2007 ASCO Annual Meeting Proceedings (Postmeeting edition) [abstract]. J Clin Oncol. 2007;25:18S. Abstract 2.
18. Ghavamzadeh A, Alimoghaddam K, Ghaffari SH, et al. Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy. Ann Oncol. 2006;17(1):131-134.
19. Mathews V, George B, Lakshmi KM, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood. 2006; 107(7):2627-2632.
20. Ravandi F, Estey E, Jones D, et al. Effective treatment of acute promyelocytic leukemia with alltrans retinoic acid, arsenic trioxide and gentuzumab ozogamicin. J Clin Oncol. 2009;27(4):504-510.
21. Hu j Liu YF, Wu CF, et al. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A. 2009;106(9):3342-3347.
22. Estey E, Garcia-Manero G, Ferrajoli A, et al. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood. 2006;107(9): 3469-3473.